BRIEF published on 07/07/2025 at 15:05, 1 year 2 months ago Applied DNA Sciences se conforme aux normes de cotation du Nasdaq Biotechnologie Sciences Appliquées De L'ADN Conformité Au Nasdaq Technologies De L'ADN LineaRx
BRIEF published on 07/07/2025 at 15:05, 1 year 2 months ago Applied DNA Sciences Complies with Nasdaq Listing Standards Biotechnology Nasdaq Compliance Applied DNA Sciences DNA Technologies LineaRx
PRESS RELEASE published on 07/07/2025 at 15:00, 1 year 2 months ago Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements Applied DNA Sciences regains compliance with Nasdaq listing rule requiring minimum bid price of $1.00 per share. Company's securities to remain listed on Nasdaq Capital Market Nasdaq Compliance Applied DNA Sciences Nasdaq Capital Market Minimum Bid Price PCR-based DNA Technologies
BRIEF published on 06/17/2025 at 22:15, 1 year 3 months ago Transition de direction chez Applied DNA : le Dr Hayward, PDG, prend sa retraite Biotechnologie Changement De Direction Valeur Actionnariale ADN Appliqué Judy Murrah
BRIEF published on 06/17/2025 at 22:15, 1 year 3 months ago Leadership Transition at Applied DNA as CEO Dr. Hayward Retires Biotechnology Shareholder Value Leadership Change Applied DNA Judy Murrah
PRESS RELEASE published on 06/17/2025 at 22:10, 1 year 3 months ago Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward Judy Murrah appointed Chairperson and CEO of Applied DNA Sciences, succeeding Dr. James A. Hayward. Experienced executive aims to lead company's innovative DNA technologies CEO Appointment Applied DNA Sciences DNA Technologies Judy Murrah Dr. James A. Hayward
BRIEF published on 05/15/2025 at 22:10, 1 year 4 months ago Applied DNA Sciences enregistre une croissance modeste de ses revenus au deuxième trimestre 2025 Croissance Des Revenus Restructuration Stratégique Résultats Financiers Du Deuxième Trimestre Tendances Biopharmaceutiques Technologie De L'ADN
BRIEF published on 05/15/2025 at 22:10, 1 year 4 months ago Applied DNA Sciences Sees Modest Revenue Growth in Q2 2025 Revenue Growth Strategic Restructuring Q2 Financial Results DNA Technology Biopharma Trends
PRESS RELEASE published on 05/15/2025 at 22:05, 1 year 4 months ago Applied DNA Reports Second Quarter Fiscal 2025 Financial Results Applied DNA Sciences, Inc. (NASDAQ:APDN) reports a 44% Y/Y increase in LineaRx segment revenues contributing to a 6% total revenue growth. Strategic priorities and financial highlights for Q2 2025 disclosed Financial Results Strategic Priorities Applied DNA Sciences LineaRx Segment Therapeutic DNA Production
BRIEF published on 05/14/2025 at 17:35, 1 year 4 months ago Applied DNA Sciences publiera ses résultats financiers du deuxième trimestre et organisera une mise à jour pour les investisseurs Sciences Appliquées De L'ADN Conférence Téléphonique Pour Les Investisseurs Priorités Stratégiques Rediffusion Du Webcast Résultats Financiers Du Deuxième Trimestre 2025
Published on 09/22/2026 at 08:00, 3 hours 20 minutes ago Coretura Selects Alloy Kore to Advance a Unique Software-Defined Vehicle Platform for Its Commercial Vehicle Customers
Published on 09/22/2026 at 08:00, 3 hours 20 minutes ago Caledonia Mining Corporation PLC: Notification of Relevant Change to Significant Shareholder
Published on 09/22/2026 at 06:45, 4 hours 35 minutes ago Akkodis and Hamburg Public Transport Association Showcase hvv mia at InnoTrans 2026, Demonstrating the Future of AI-Powered Mobility
Published on 09/22/2026 at 06:45, 4 hours 35 minutes ago Akkodis et l’association des transports publics de Hambourg présentent hvv mia à InnoTrans 2026 et montrent comment l’IA transforme la mobilité.
Published on 09/22/2026 at 06:45, 4 hours 35 minutes ago Akkodis en Hamburger Verkehrsverbund presenteren hvv mia op InnoTrans 2026 en tonen de toekomst van AI-gedreven mobiliteit
Published on 09/22/2026 at 10:30, 50 minutes ago Elke Eckstein appointed to the Supervisory Board of R. STAHL AG
Published on 09/22/2026 at 10:05, 1 hour 14 minutes ago Hedia Secures Regulatory Approval to Expand Digital Diabetes Care to Pediatric Patients
Published on 09/22/2026 at 09:55, 1 hour 24 minutes ago Original-Research: HORNBACH Holding AG & Co. KGaA (von Quirin Privatbank Kapitalmarktgeschäft): Buy
Published on 09/21/2026 at 18:19, 17 hours ago Déclaration de rachats d'actions effectués par la Compagnie de Saint-Gobain du 14 au 18 septembre 2026
Published on 09/21/2026 at 18:19, 17 hours ago Reporting on share buyback transactions carried out between September 14 and September 18, 2026
Published on 09/21/2026 at 18:01, 17 hours 18 minutes ago Partnership agreement signed between Manitou Group and HD Construction Equipment
Published on 09/21/2026 at 17:46, 17 hours 34 minutes ago WEB SA - STATUTORY HALF-YEAR RESULTS AS OF 30/06/2026
Published on 09/21/2026 at 17:46, 17 hours 34 minutes ago WEB SA - RESULTATS SEMESTRIELS STATUTAIRES AU 30/06/2026
